Is there any evidence linking adalimumab use to the development of posterior reversible encephalopathy syndrome in patients with autoimmune conditions?
Abstract
The evidence suggests a potential but not well-documented link between adalimumab use and neurological events, including PRES; further research is needed to clarify this risk in patients with autoimmune conditions.
Fields of Study & Subjects
Neurological Complications and Syndromes
Vasculitis and related conditions
Cerebral Venous Sinus Thrombosis
Publication details
- Journal / source
- Zenodo (CERN European Organization for Nuclear Research)
- Publication date
- 29 January 2026